CSIMarket Company Name, Ticker, Suppliers, else..
 
Tourmaline Bio Inc   (NASDAQ: TRML)
 
Price: $47.9800 $0.00 0.000%
Day's High: $48 Week Perf: 0.15 %
Day's Low: $ 47.98 30 Day Perf: 0.52 %
Volume (M): 783,700 52 Wk High: $ 48.27
Volume (M$): $ 37,602 52 Wk Avg: $47.86
Open: $47.98 52 Wk Low: $47.66



 Market Capitalization (Millions $) 1,236
 Shares Outstanding (Millions) 26
 Employees 74
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -88
 Cash Flow (TTM) (Millions $) -39
 Capital Exp. (TTM) (Millions $) 0

Business Description


Tourmaline Bio Inc is a biotechnology company specializing in the development of innovative therapies and diagnostic tools for the detection and treatment of various diseases. The company focuses on utilizing the unique properties of tourmaline, a mineral known for its piezoelectric and pyroelectric properties, to create groundbreaking medical solutions. By harnessing the energy generated by tourmaline crystals, Tourmaline Bio aims to improve the accuracy and effectiveness of diagnostics, as well as enhance drug delivery and tissue regeneration. The company's vision is to revolutionize healthcare by capitalizing on the potential of tourmaline technology in the field of biomedicine.


   Company Address: 27 West 24th Street New York 10010 NY
   Company Phone Number: 481-9832   Stock Exchange / Ticker: NASDAQ TRML


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMGN   -4.35%    
DNA        1.01% 
EXEL   -3.64%    
KRYS   -5.23%    
MRNA        1.96% 
NVAX   -9.42%    
• View Complete Report
   



Clinical Study

Tourmaline Bio Shines Through Second Quarter 2025 Financial Highlights and Strategic Insights

Published Wed, Aug 13 2025 11:37 AM UTC

The pharmaceutical landscape is continuously evolving, and companies like Tourmaline Bio exemplify this dynamic environment. In their second quarter of 2025, Tourmaline Bio released a comprehensive financial report highlighting significant achievements and strategic initiatives. This article synthesizes the key findings from the report and assesses their implications for th...
Clinical Study

In an exciting confluence of innovation and strategy, Tourmaline Bio recently showcased its pioneering focu...

Published Tue, Dec 10 2024 1:30 PM UTC

Spotlight on Cardiovascular Inflammation: Tourmaline Bio’s Strategic Advances Revealed at Investor Day In an exciting confluence of innovation and strategy, Tourmaline Bio recently showcased its pioneering focus on cardiovascular inflammation during its much-anticipated Investor Day event. The company s latest clinical advancements and strategic plans were in the spotlight...
Clinical Study

Groundbreaking Insights into Cardiovascular Health Tourmaline Bio Unveils Phase 2 TRANQUILITY Study at ASPC Congress ...

Published Fri, Aug 2 2024 8:30 PM UTC

Tourmaline Bio, a pioneering company in developing therapeutics for cardiovascular health, recently unveiled the design of its Phase 2 TRANQUILITY study at the esteemed American Society of Preventive Cardiology (ASPC) Congress 2024. This pivotal event, held in location from start date to end date, gathered leading experts, clinicians, and researchers in the field of cardiolo...
Clinical Study

CSIMarket.com ' The initiation of Phase 2 clinical trials for TOUR006 marks a significant milestone in cardiovascular disease management. This article explores the implications of Tourmaline Bio's recent advancements, with a particular focus on the TRANQUILITY trial, the mechanisms of TOUR006, and its potential impact on clinical practice.br...

Published Thu, May 16 2024 11:01 AM UTC

Emerging Therapeutic Frontiers: Tourmaline Bio s TOUR006 as a Potential Game-Changer in Cardiovascular Disease Management CSIMarket.com The initiation of Phase 2 clinical trials for TOUR006 marks a significant milestone in cardiovascular disease management. This article explores the implications of Tourmaline Bio s recent advancements, with a particular focus on the T...
Shares

Tourmaline Bio Raises $150 Million in Successful Public Offering to Advance Revolutionary Medicines for Immune and Inflammatory Diseases

Published Thu, Jan 25 2024 12:00 PM UTC

Tourmaline Bio Announces Successful Pricing of Public Offering of Common Stock
Tourmaline Bio, Inc. (Tourmaline), a late-stage clinical biotechnology company specializing in the development of transformative medicines for patients with immune and inflammatory diseases, made an exciting announcement today. The company revealed the pricing of its underwritten public offeri...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 4.77
PEG (TTM) -

Financial Strength Current
Quick Ratio 24.04
Working Capital Ratio 25.04
Leverage Ratio (MRQ) 0.04
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -3.45 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash 9.29 $
Book Value 10.06 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -1,195,595
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.